Autoreactive Anti-Ro/SSA IgE To Determine Primary SjögRen's Syndrome's Disease Activity

Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE SAINT ETIENNE · Dec 22, 2016

Keywords

ClinConnect Summary

This clinical trial is studying a specific type of antibody called anti-Ro/SSA IgE to see if it can help measure the activity of Primary Sjögren's Syndrome (pSS), a long-term condition that can cause discomfort and affect various organs in the body. The researchers want to find out if patients with active disease (indicated by a specific score on a disease activity index) have higher levels of this antibody. By understanding this connection, doctors may be able to better monitor and manage the disease for their patients.

To participate in the study, individuals need to have a confirmed diagnosis of Primary Sjögren's Syndrome and must be willing to sign a consent form. Unfortunately, those with other autoimmune diseases or who have recently received specific treatments may not be eligible. If you join, you will have your anti-Ro/SSA IgE levels tested and share information about your health, which will help researchers learn more about pSS and its effects. This study is currently recruiting participants of all genders, aged 65 to 74.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Primary Sjögren's syndrome according to the American-European Consensus Criteria)
• • Informed and having signed the study consent form
• Exclusion Criteria:
• • Secondary Sjögren's syndrome
• • Other systemic autoimmune disease (e.g. rheumatoid arthritis, AntiNeutrophil Antibodies (ANCA) -associated vasculitis, mixed connective tissue disease...)
• • Incapacity or refusal to sign the informed consent form
• • Incapacity or refusal to perform the follow-up examinations required by the study
• • Has received abatacept, sifalimumab, rontalizumab, anifrolumab, belimumab, Tumor Necrosis Factor (TNF) antagonists or interferon during the 6 months prior to the inclusion
• • Has any current signs or symptoms of active infection